Caribou Biosciences Inc

NASDAQ:CRBUUnited States

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Contact Information

Headquarters

2929 7TH STREET, STE 120BERKELEY, CA, United States 94710

Phone

510-982-6030

Fax

302-531-3150

Executives

Independent Chairman of the Board

Andrew Guggenhime

President, Chief Executive Officer, Co-Founder, Director

Rachel Haurwitz

Interim Principal Financial Officer and Interim Principal Accounting Officer

Ryan Fischesser

Chief People Officer

Reigin Zawadzki

Chief Technology Officer

Tim Kelly